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Abstract The extracellular domains of the TrkA and TrkB 
neurotrophin receptors contain defined structural modules such 
as immunoglobulin-like domains and leucine-rich motifs (LRMs) 
]Schneider and Schweiger, Oncogene 6 (1991) 1807-1811]. Re- 
cently, the second LRM of TrkA was identified as a functional 
nerve growth factor (NGF) binding site ]Windisch et al, J. Biol. 
Chem. (1995) in press]. A peptide corresponding to this region 
effectively bound NGF and blocked binding of NGF to the recom- 
binant extracellular domain of TrkA. The corresponding TrkB 
peptide exhibited the same effects with respect to brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neuro- 
trophin-4 (NT-4), indicating that all three TrkB ligands utilize 
this same binding site. Isolated LRMs therefore embody inde- 
pendent functional entities. 
Key words." Affinity chromatography; Binding site; Leucine- 
rich motif; Nerve growth factor; Peptide blocking; Tyrosine 
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I. Introduction 
TrkA is the biologically functional receptor for nerve growth 
factor (NGF) [9,13], whereas its homolog TrkB binds three 
different neurotrophins [3,8,16,24,36] namely brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neu- 
rotrophin-4 (NT-4) [5,14,15,31,32]. The extracellular domains 
of Trk-type receptors harbor a modular mosaic of potential 
ligand binding modules, namely two immunoglobulin (Ig)-like 
domains and an LRM3-cassette consisting of a tandem array 
of three leucine-rich motifs (LRMs) flanked by cysteine-rich 
clusters [28]. These structures were discovered by the applica- 
tion of sequence comparison algorithms capable of detecting 
even highly degenerate motifs [30]. 
LRMs are short amino acid sequences of 22 to 30 residues 
that are tandemly repeated in an individual protein and contain 
hydrophobic residues at conserved positions [27,29]. Repeats 
of LRMs have been known as potent mediators of strong and 
specific homo- or heterophilic protein-protein i teractions. 
They have been found in proteins as diverse as human platelet 
glycoprotein IX [7], Drosophila Toll [11] and Drosophila 
Chaoptin [18], where they mediate cell-cell interactions and 
communication, and yeast adenylate cyclase, where they form 
the interaction site with the Ras protein [35]. However, only 
recently the first single LRM with a defined function was iden- 
tified. An NGF binding site was mapped to the second LRM 
of TrkA using a recombinant receptor approach [39]. 
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Based on this information we synthesized a 24 amino acid 
peptide corresponding to this region of TrkA (L2A) to investi- 
gate whether this module represents an independent functional 
and structural unit in that it can bind NGF and, by doing so, 
inhibit NGF binding to the recombinant extracellular domain 
of TrkA. To investigate whether this 24 amino acid LRM is the 
smallest possible functional unit capable of mediating NGF 
binding and if a different phasing of the LRM repeats as sug- 
gested by Kobe and Deisenhofer [17] leads to the same results, 
a peptide with the same sequence as L2A but lacking three 
amino acids at the N-terminus as well as a recombinant fusion- 
protein shifted five residues toward the N-terminus with respect 
to L2A were produced and tested for their ability to block NGF 
binding to TrkA. 
Given the information about he NGF binding site within the 
TrkA receptor, it was obvious to extend the application of this 
peptide approach to TrkB. TrkA and TrkB share 37% amino 
acid sequence identity in the extracellular domains and 75% in 
the kinase domains [23,28]. Despite this high degree of similar- 
ity, TrkB is a much more versatile receptor than TrkA in that 
it binds three different ligands [24] with clearly distinguishable 
pharmacological characteristics [2,22,25,26] leading to distinct 
biological effects [8,14,15]. In order to show whether the second 
LRM also plays a role in ligand binding in the TrkB receptor, 
a peptide corresponding to this region (L2B) was synthesized 
and characterized in the same way as L2A. Investigating the 
inhibitory effect of different concentrations of L2B on the bind- 
ing of BDNF, NT-3 and NT-4 to the recombinant extracellular 
domain of TrkB should give precise information in qualitative 
and quantitative t rms on the role of this region in the binding 
of the different ligands. 
2. Experimental 
2.1. Neurotrophins 
Recombinant E. coli/vaccinia virus expressed mouse BDNF, mouse 
NT-3 [6], and Xenopus NT-4 were kind gifts of R. Kolbeck, G. Dechant, 
and Y.-A. Barde. Mouse submaxillary gland NGF-fl was purchased 
from Sigma Immuno Chemicals. [~zSI]BDNF, [l:SI]NT-3, and [125I]NT-4 
were prepared using the lactoperoxidase method, [~25I]NGF-fl was pur- 
chased from Amersham. 
2.2. Peptides 
Peptides corresponding tothe second leucine-rich motif of rat TrkA 
and rat TrkB were chemically synthesized and purified. The phasing of 
the leucine-rich motif peptides used in this work was chosen in accord- 
ance with the data obtained in previous tudies [38]. The amino acid 
sequences were derived from the published cDNA sequences [22,23]. 
Both peptides were 24mers with the sequences NH2-TIVKSGLRFVAP- 
DAFHFTPRLSHL-cooH for TrkA (peptide 'L2A') and NH2- 
TIVDSGLKFVAYKAFLKNGNLRHI-cooH for TrkB (peptide 
'L2B'), respectively. The sequence of the control peptide L2A(-3) is 
identical to that of L2A but lacks the first three amino acids (NH 2- 
KSGLRFVAPDAFHFTPRLSHL-cooH). 
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2.3. Construction of peptide affinity columns 
The L2A and the L2B peptides were covalently coupled via amide 
bonds to N-hydroxysuccinimide ester-activated cross-linked agarose 
gel beads (Affi-Gel 10, Bio-Rad) essentially according to the manufac- 
turer's instructions. 10 mg of the respective peptide were incubated with 
2 ml of precycled column material in 0.1 M MOPS, pH 7.0 with gentle 
agitation over night. Remaining active ster groups were blocked by the 
addition 0.2 ml 1 M ethanolamine pH 8.0 followed by a further incuba- 
tion period of 2 h. The column materials were washed with at least ten 
volumes of phosphate buffered saline (PBS) containing 1M NaC! and 
1 mg/ml bovine serum albumin (BSA) before using them in the experi- 
ments. 
2.4. Binding of [125I]NGF and [125I]BDNF to the peptide affinity 
columns 
Two times 0.5 ml of the L2A and the L2B affinity column materials 
were packed into small columns and washed with ten column volumes 
PBS containing 1 mg/ml BSA and 0.1 mg/ml cytochrome c (bovine 
heart) to reduce non-specific binding. 0.2 ng (~23000 cpm) of [J2SI]NGF 
in 200/11 of the above buffer were applied to an L2A column. Starting 
at this point, fractions of 0.5 ml were taken. The column was washed 
with six volumes of buffer before adding 5 mg of the L2B peptide in 
0.5 ml of buffer (first elution step). Again the column was washed with 
three volumes of buffer. Then 5 mg of the L2A peptide in 0.5 ml of 
buffer were added (second elution step) followed by another wash of 
five column volumes. All fractions were measured in a gamma counter. 
Three additional analogous experiments were performed. [125I]NGF 
was applied to an L2B column followed by elution steps with soluble 
L2B and L2A. [125I]BDNF was also applied to an L2B column followed 
by elution steps with soluble L2A and L2B. Finally, [~25I]BDNF was 
applied to an L2A column followed by elution steps with soluble L2A 
and L2B. Again, all obtained fractions were measured in a gamma 
counter. 
2.5. Production and purification of recombinant receptor proteins 
The regions encoding the extracellular domains of rat TrkA (C36- 
E416) and rat TrkB (C21-E417) as well as of the region encoding L2A' 
(E92-Nl15 of rat TrkA) were amplified from embryonal rat brain 
mRNA by RT-PCR and cloned into the pMalVM-p expression vector. 
The sequences of the fragments were identical to the ones published in 
the literature [22,23]. The recombinant Maltose Binding Protein 
(MBP)-TrkA/B fusion proteins were expressed in E. coli and purified 
by amylose resin affinity chromatography essentially as described pre- 
viously [38,39]. For the negative controls a fusion protein composed of 
MBP and fl-galactosidase (MBP-flGal) was expressed. The purified 
proteins were extensively dialysed against 20 mM Tris-HC1 pH 7.4, 200 
mM NaCI, 1 mM EDTA (column buffer) before using them in the 
experiments. The production of the L~. 5 3C2 and the C~LH5 proteins is 
described in [39]. 
2.6. Binding inhibition assays 
2.6.1. Immobilization of recombinant receptors. 100 ng (2.5 pmol) 
of recombinant protein/assay were batch loaded onto 5 ,ul of amylose 
resin in 25 pl of column buffer. After centrifuging, the supernatant was 
removed and the pellet washed three times with column buffer. In order 
to minimize non-specific binding, the column material was resuspended 
in 85 ¢tl column buffer + 5 mg/ml BSA + 0.1 mg/ml cytochrome c (bo- 
vine heart) + 2 mg/ml heat denatured BSA + 0.1 mg/ml heat-denatured 
cytochrome c and incubated with gentle shaking for 30 rain. The dena- 
tured proteins were included to give a more solid amylose resin pellet 
after centrifugation. 
2.6.2. Inhibition assays. [t251]NGF or [t25I]BDNF were incubated 
with gentle shaking at 20°C for 90 min with different amounts of L2A, 
L2B or L2A(-3) in a total volume of 10 ¢tl. The buffer used was column 
buffer containing 5 mg/ml BSA and 0.1 mg/ml cytochrome c.After this 
period, 90 pl of the corresponding immobilized recombinant receptor 
were added followed by another 90 min incubation to reach equilibrium 
binding. The final concentrations of the peptides ranged from 0 M, 
1.86 x 10 -8 M to 3.72x 10 -5 M. The final concentration of both 
[1251]NGF and [~zSI]BDNF was 1 x 10 -9 M in all experiments. After 
centrifuging for 3 min, the supernatants were transferred tofresh tubes 
(SN1). The pellets were washed three times in column buffer containing 
20 mM maltose to elute the receptor-ligand complexes. The superna- 
tants of all three centrifugation steps were combined in a new tube 
(SN2). SNI, SN2 and the amylose resin pellet were measured on a 
'Cobra Auto Gamma' counter (Packard). SN1 therefore represents free 
[1251]neurotrophin, SN2 specifically bound [J25I]neurotrophin. The 
small amounts of radioactivity trapped in the pellet were added to the 
free [~25I]neurotrophin. For each concentration of [1251]NGF/ 
[~251]BDNF a MBP-flGal control was included to detect non-specific 
binding to MBP. In general non-specific binding was very low. It was 
subtracted from the value for specific binding in each case. All binding 
reactions were carried out in duplicate. Differences between duplicate 
values were generally small. K~ values were calculated according 
to [1]. 
3. Results and discussion 
To determine whether the second leucine-rich mot i f  of TrkA 
can form the proper structures and function in the absence of 
its natural  molecular context or of a supporting carrier protein 
[39], the ability of a peptide corresponding to this functional 
module (amino acids 97 to 120 of rat TrkA according to 
Meakin et al. [22]) was synthesized (L2A). The peptide was 
covalently coupled to an agarose column matrix as described 
in section 2. If the L2A peptide represents a functional entity, 
the resulting column material should be suitable for the applica- 
tion as a highly specific neurotrophin affinity chromatography 
matrix. To test this hypothesis, a respective column was loaded 
with radioactively labelled (iodinated) NGF ([125I]NGF). The 
columns were washed with several volumes of buffer but only 
about 70% of the radioactivity loaded onto the column reap- 
peared in the flow through fractions (Fig. 1). This was a strong 
indication that [~zSI]NGF had actually bound to the immobi- 
lized L2A. This again indicates that this isolated leucine-rich 
motif, even when covalently attached to a column matrix, rep- 
resents a functional unit in that it forms a structure that posi- 
tions its side chains at the adequate 3D coordinates to properly 
interact with the crucial residues of the ligand. It is therefore 
one of the smallest self-contained growth factor binding sites 
known at this point. 
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Fig. 1. Binding of [12~I]NGF to a TrkA L2A affinity column and of 
[~zSI]BDNF to a TrkB L2B affinity column. The experiments were 
performed as described in section 2. [125I]NGF or [~2~I]BDNF were 
applied to L2A and L2B affinity columns, the columns washed and the 
[~zSI]neurotrophins eluted in two steps by the addition of the Trk pep- 
tides. NCP (non-competitive p ptide) and CP (competitive peptide) 
indicate the addition of the L2A or L2B peptides. In experiments 
involving [~25I]NGF NCP=L2B and CP=L2A, in those involving 
[J25I]BDNF NCP-L2A and CP=L2B, so that in each case the peptide 
derived from the non-natural receptor was added first. 
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Fig. 2. Effective competition by L2A/L2B of [~25I]neurotrophin bi ding to the TrkA/TrkB recombinant extracellular domains. The experiments were 
performed as described in section 2. (a) L2A effectively blocks binding of [~2-~I]NGF to the recombinant TrkA extracellular domain. [~25I]NGF, 
[~zSI]BDNF, [LzSI]NT-3, and [125I]NT-4 were preincubated with concentrations of L2A ranging from 0 M, 1.86 × 10 -8 M to 3.72 × 10 -5 M and 
subsequently added to the immobilized recombinant extracellular domains of TrkA ([I25]]NGF) or TrkB ([L25I]BDNF, [L25][]NT-3, and [1251]NT-4). 
After equilibrium binding had been reached, the amount of [~25I]neurotrophin bound to the respective domain was determined. Analogous experiments 
were performed with the N-terminally truncated L2A(-3) peptide, but only the curve for [~25I]NGF is shown here since for the other [~25I]neurotrophins 
the curve were indistinguishable from the ones obtained with L2A. All data points are means of duplicates. (b) L2B effectively blocks binding of 
[~25I]BDNF, [~251]NT-3, and [~25I]NT-4 to the recombinant TrkB extracellular domain. The experiments were performed in an identical fashion as 
in (a) except hat L2B was used as an inhibitor. All data points are means of duplicates. 
The column was subjected to two elution steps designed to 
yield information on the precision of the observed interaction. 
In the first elution step, a heterologous peptide corresponding 
to the second LRM of rat TrkB (L2B) was applied in high 
excess to assess the specificity of the interaction between 
[~25I]NGF and L2A. L2B shares 13 identical amino in a total 
of 24 with L2A making it the ideal tool for such a purpose. No 
detectable amounts of [~25I]NGF eluted from the column after 
the addition of L2B (Fig. 1). In the second elution step an excess 
of soluble L2A was applied to the column. If the binding of 
[~25I]NGF to the column had been actually due to specific inter- 
action with the immobilized L2A peptide, this step should lead 
to a specific, competitive elution of the radioligand. In fact, the 
virtually all of the [~25I]NGF that had bound to the column 
eluted in a distinct peak when the soluble L2A peptide was 
added (Fig. 1) proving that the L2A peptide on the column 
indeed accounts for the observed binding phenomena. The sec- 
ond LRM of TrkA therefore mbodies a binding site of high 
specificity enabling it to solely bind NGF among the array of 
highly homologous neurotrophins. 
Further proof of the specificity of the interaction between 
NGF and L2A was obtained by loading [nzsI]BDNF onto an 
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Fig. 3. Importance of phasing for the activity of L2A. The entire 24 amino acids of the second LRM of TrkA (L2A) are required for proper binding 
of NGF. Proteins disrupting this LRM from either side as well as peptide truncated by three amino acids at the N-terminus [L2A(-3)] were inactive. 
A protein expressed in the boundaries suggested by Kobe and Deisenhofer [17] (L2A') was also unable to bind NGF. 
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Fig. 4. Alignment of the second leucine-rich motifs of TrkA and TrkB 
receptors from different species. The rat TrkA [22] and rat TrkB [23] 
sequences correspond to the ones of the L2A and L2B peptides used 
in this work. The sequences ofhuman TrkA, mouse TrkB, and chick 
TrkB were taken from Martin-Zanca et al. [19], Klein et al. [12], and 
Dechant et al. [3], respectively. The localizations of the motifs within 
the respective proteins are indicated by the numbers on either side of 
the sequences. Residues which are identical between all species in a 
given Trk-type are shown in bold upper-case, residues which vary are 
shown in standard lower-case. In the consensus sequences a 'b' indicates 
a basic residue, an 'h' a hydrophobic residue, an 's' a residue with a 
small side chain, and an 'x' any residue. The last line represents he 
general consensus sequence of the second LRM of TrkA and TrkB with 
the information from all species combined. The hydrophobic residues 
characteristic of a leucine-rich motif are underlined. 
L2A column as described above for [~25I]NGF. In contrast o 
['25I]NGF, however, the entire amount of [125I]BDNF radioac- 
tivity was found in the flow through (Fig. 1). Similar experi- 
ments were conducted with [125I]NT-3 and [125I]NT-4 leading to 
the same results as with [~25I]BDNF. Therefore, the second 
LRM of TrkA indeed represents a binding site reserved exclu- 
sively for NGF. 
After this novel approach ad turned out to work for L2A, 
it was utilized to address the question of neurotrophin binding 
within the LRM3-cassette of TrkB. TrkB, in contrast to TrkA, 
has three different ligands, BDNF, NT-3 and NT-4 [8,24] and 
therefore represents a much more complex system. Surpris- 
ingly, [J25I]BDNF actually bound to the L2B column with an 
affinity comparable to that of the interaction between L2A and 
NGF. Analogous experiments using L2B columns were con- 
ducted with [~25I]NT-3 and [~25I]NT-4 leading to similar results 
as with [125I]BDNF even though binding of these neurotrophins 
to the covalently immobilized neurotrophin was much less pro- 
nounced than that of [~25I]BDNF. We could therefore identify 
the second LRM as a potent binding site for all three TrkB 
ligands. This is highly interesting since a mere 24 (or eleven 
considering that 13 are identical to that of the second LRM of 
TrkA) are capable of specifically recognizing three different 
neurotrophins. 
Even though these results are highly satisfying in qualitative 
terms, i.e. in terms of the underlying highly specific biochemical 
mechanism, the observed binding phenomena pparently can 
not quantitatively account for the binding affinity observed in 
vivo [3,22,25,34] or using recombinant receptor proteins [39]. 
It must therefore be assumed that the capacity of the columns 
was aggravated by the fact that a large percentage of the pep- 
tides was either coupled to the matrix in a way that abolished 
binding affinity or was simply folded in an incorrect fashion 
[4,10,20]. Some peptides only exhibit a weak tendency to adopt 
a defined tertiary structure so that in a steady state balance only 
a small number of peptides exists in an active form at a given 
time point [10]. Furthermore, there are prominent examples of 
peptides that need the support of carrier proteins in order to 
acquire the correct conformation and thus function properly 
[33,37]. In the case of the L2A and L2B peptides this might well 
be the case since we have previously shown binding of 
['25I]NGF with high affinity (Kd'-~ 1 nM) to a recombinant fu- 
sion protein of the E. coli maltose binding protein (MBP) and 
the second LRM of TrkA. Most likely a combination of the 
phenomena described above accounts for the low capacity of 
the peptide columns observed in our experiments. 
To obtain more precise information on the role these binding 
modules play in the biochemistry of TrkA and the TrkB recep- 
tors, the effect of these peptides (L2A, L2A(-3), and L2B) in 
inhibiting the binding of the different neurotrophins to the 
immobilized recombinant TrkA and TrkB extracellular do- 
mains was investigated asdescribed in section 2. In these exper- 
iments the L2A peptide led to a pronounced inhibition of 
[125I]NGF binding to TrkA but it had no effect on the binding 
of [125I]BDNF, [1251]NT-3 and [125I]NT-4 to TrkB even when 
present at very high concentrations (Fig. 2a). The N-terminally 
truncated L2A(-3) peptide, however, had practically no effect 
on [~25I]NGF binding to TrkA even when present at a 1000fold 
excess over the TrkA extracellular domain (Fig. 3). 
We also tested the ability of [125I]NGF to bind to recombi- 
nant fusion-proteins disrupting the second LRM of TrkA from 
either side [38] as well as to a fusion-protein with the LRM 
boundaries uggested by Kobe and Deisenhofer [17], which 
means that the entire 24 residues of L2A are shifted five amino 
acids toward the N-terminus of TrkA. None of these proteins 
exhibited significant binding affinity for [~25I]NGF (Fig. 3). This 
supports our hypothesis that not a certain set of individual 
residues within the second LRM of TrkA, but much rather the 
entire structure is required for efficient ligand binding and that 
correct phasing is a prerequisite for a leucine-rich motif to 
function properly. 
In conformity with its binding capacities, the L2B peptide 
showed a wider range of inhibitory effects with respect o the 
different neurotrophins. It inhibited the binding of all three 
TrkB ligands, BDNF, NT-3 and NT-4, to the recombinant 
extracellular domain of TrkB. It had no effect on the binding 
of NGF to TrkA (Fig. 2b). 
These results clearly indicate that the second LRM plays a 
significant role in the binding of neurotrophin to TrkA as well 
as TrkB. However, the efficacy of the interference of the L2A 
or L2B peptides with the binding of the various neurotrophins 
was not as great as could be expected from previous experi- 
ments involving recombinant proteins [39]. Calculation of the 
inhibition constants for the interaction between the peptides 
and the neurotrophins yielded K~ values in the range of 2 × 10 -8 
M to 1 × 10 -7 M which is at least a factor 20 short of the 
affinities observed on recombinant receptors as well as on cells 
ectopically expressing TrkA [9,22] or TrkB [3,31] receptors. 
This supports our interpretation of the low capacity observed 
with L2A and L2B affinity columns, i.e. that only a small 
portion of the peptides is folded in the same fashion as the 
corresponding region within the entire receptor protein. 
The biochemical complexity displayed by these short binding 
site peptides corroborates the notion that homologous amino 
acid sequence modules can, simply by exchanging a few crucial 
residues during evolution, assume decidedly different and 
highly specific functions. It is also consistent with this evolu- 
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tionary view that, in the Trk-type receptor most highly con- 
served between species, TrkC, the second LRM exhibits the 
highest degree of conservation of all three LRMs in the LRM 3- 
cassette with variations at only two of 24 positions, Fig. 4 shows 
an alignment of the sequences of the second leucine-rich motifs 
of TrkA and TrkB receptors from different species. There is a 
single conservative exchange between rat and human TrkA. It 
will be highly interesting to see if this conservation is also 
preserved when TrkA sequences from species evolutionarily 
more distant o mammalians become known since this would 
give important clues to how binding specificity is achieved in 
this receptor. The second LRM of TrkB shows a higher degree 
of sequence variation. As a result of the complexity inherent in 
having to deal with three different ligands, it is impossible at 
this point to identify specific 'binding residues' within the sec- 
ond LRM of TrkA or TrkB. It seems more likely that the entire 
LRM structure in combination with distinct sets of residues 
account for the high biochemical complexity of these short 
binding motifs. 
The biological importance of the second LRM of Trk recep- 
tors as a major neurotrophin binding site is underscored by in 
vivo experiments recently performed by our group where L2A 
peptides led to the specific degeneration of NGF dependent 
neurons in the rat brain (C. Humpel, J.M. Windisch, and R. 
Schneider, unpublished observations). 
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